Mechanisms Involving PPAR-Gamma

The 2-year investigator-assessed event-free survival rate in the intent-to-treat population of patients with high-risk head and neck squamous cell carcinoma was 67.4% with atezolizumab.

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

Pembrolizumab plus standard-of-care chemotherapy improved survival in patients with endometrial cancer vs chemotherapy alone.

In this episode of Targeted Talks, Nini Wu, MD, MBA, shares her insights on the ever-changing world of technology in community oncology.

A biologics license application for subcutaneous amivantamab combined with recombinant human hyaluronidase has been submitted to the FDA for NSCLC indications.

Anthony Conley, MD, discussed findings from a phase 1/2 study investigating the oncolytic virus AdAPT-001 in patients with solid tumors presented at ASCO 2024.